MedTech Company CollPlant Launches New HQ, R&D Center In Israel

Regenerative medicine company CollPlant is launching its new headquarters and R&D center in Israel, the company announced Wednesday.

Collplant will use the R&D center for development of its products, including BioInks for 3D bioprinting of tissues and organs, and dermal fillers for medical aesthetics.

Founded in 1981 in Israel, CollPlant develops, manufactures and commercializes products for tissue repair and organ manufacturing from rhCollagen (recombinant human collagen.)

“This winning combination of human capital and technology enables us to take a significant step forward through development of new state-of-the-art products and facilitating significant business partnerships with leading corporations” said CollPlant CEO Yehiel Tal.

CollPlant produces rhCollagen from tobacco plants which genetically engineered with five human genes essential for collagen production.  CollPlant’s products are based on rhCollagen.

In the fourth quarter of 2018, CollPlant signed a global license and commercialization agreement with United Therapeutics Corporation for the use of its BioInk for the 3D bioprinting of lung scaffolds with a longterm goal to manufacture an unlimited supply of transplantable lungs for patients with serious medical issues. The agreement is subject to approval by the US Food and Drug Administation.

United Therapeutics will use the BioInk in its manufacturing process and establish a facility to manufacture CollPlant’s rhCollagen and BioInk in the US.